Organon & Co (NYSE: OGN) kicked off on Monday, down -22.93% from the previous trading day, before settling in for the closing price of $9.16. Over the past 52 weeks, OGN has traded in a range of $8.01-$19.05.
A company in the Healthcare sector has dropped its sales by -23.49% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -6.35%. With a float of $259.02 million, this company’s outstanding shares have now reached $259.96 million.
Organon & Co (OGN) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Organon & Co is 0.36%, while institutional ownership is 83.52%. The most recent insider transaction that took place on May 14 ’25, was worth 100,591. In this transaction Director of this company bought 12,469 shares at a rate of $8.07, taking the stock ownership to the 12,469 shares. Before that another transaction happened on May 07 ’25, when Company’s Chief Human Resources Officer bought 5,500 for $8.77, making the entire transaction worth $48,235. This insider now owns 62,974 shares in total.
Organon & Co (OGN) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported 0.87 earnings per share (EPS), lower than consensus estimate (set at 0.9) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.9 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.40% during the next five years compared to -23.49% drop over the previous five years of trading.
Organon & Co (NYSE: OGN) Trading Performance Indicators
Take a look at Organon & Co’s (OGN) current performance indicators. Last quarter, stock had a quick ratio of 1.13. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.29. Likewise, its price to free cash flow for the trailing twelve months is 2.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.69, a number that is poised to hit 0.94 in the next quarter and is forecasted to reach 4.04 in one year’s time.
Technical Analysis of Organon & Co (OGN)
Let’s dig in a bit further. During the last 5-days, its volume was 10.34 million. That was better than the volume of 4.46 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 20.86%.
During the past 100 days, Organon & Co’s (OGN) raw stochastic average was set at 5.79%, which indicates a significant decrease from 6.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.35 in the past 14 days, which was lower than the 0.36 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.87, while its 200-day Moving Average is $11.48. However, in the short run, Organon & Co’s stock first resistance to watch stands at $7.53. Second resistance stands at $8.01. The third major resistance level sits at $8.37. If the price goes on to break the first support level at $6.69, it is likely to go to the next support level at $6.33. The third support level lies at $5.85 if the price breaches the second support level.
Organon & Co (NYSE: OGN) Key Stats
The company with the Market Capitalisation of 1.84 billion has total of 259,966K Shares Outstanding. Its annual sales at the moment are 6,403 M in contrast with the sum of 864,000 K annual income. Company’s last quarter sales were recorded 1,594 M and last quarter income was 145,000 K.
